Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
21. |
ECCT/20/06/01 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults |
Principal Investigator(s) 1. Prof Walter Jaoko Godfrey Jaoko Site(s) in Kenya 1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county) |
View |
22. |
ECCT/19/11/03 | A Pilot BE study for Enalpril 5mg A bioequivalent pilot study of a locally-produced brand of enalapril tablets: a key step towards implementation of bioequivalent study regulatory requirements in East Africa |
Principal Investigator(s) 1. Simon Njoroge Njenga Site(s) in Kenya Kenya Medical Research Institute |
View |
23. |
ECCT/19/08/01 | Use of malaria infection by injection to study malaria transmission Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites |
Principal Investigator(s) 1. Melissa Kapulu 2. Philip Bejon Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
24. |
ECCT/19/03/01 | Validation of syringe extension device Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures |
Principal Investigator(s) 1. Stephen Gwer 2. Aparna Ramanathan Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kisumu County Hospital (Kisumu county) 3. God\'s Will Clinic (Kisumu county) 4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county) |
View |
25. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
View |